Kesatuan Eropah - Iceland - EMA (European Medicines Agency)

sanofi winthrop industrie - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - blóðþurrðandi lyf - duoplavin er ætlað til að koma í veg fyrir beinþrýstingslækkandi aukaverkanir hjá fullorðnum sjúklingum sem taka bæði klópídógrel og asetýlsalisýlsýru (asa). duoplavin is a fixed-dose combination medicinal product for continuation of therapy in:non st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention (pci);st segment elevation acute myocardial infarction (stemi) in patients undergoing a stent placement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy. nánari upplýsingar er að vísa til kafla 5.

Kesatuan Eropah - Iceland - EMA (European Medicines Agency)

paion deutschland gmbh - eravacycline - infection; bacterial infections - sýklalyf fyrir almenn nota, - xerava er ætlað fyrir meðferð flókið kviðarholi sýkingum (ciai) hjá fullorðnum. Íhuga ætti að opinbera leiðsögn á réttri notkun af sýklalyfjum.

Kesatuan Eropah - Iceland - EMA (European Medicines Agency)

a. menarini industrie farmaceutiche riunite s.r.l. - delafloxacin meglúmíni - samfarir í bandalaginu - sýklalyf fyrir almenn nota, - quofenix is indicated for the treatment of the following infections in adults:acute bacterial skin and skin structure infections (absssi),community-acquired pneumonia (cap), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4. 4 og 5. Íhuga ætti að opinbera leiðsögn á réttri notkun af sýklalyfjum.

Kesatuan Eropah - Iceland - EMA (European Medicines Agency)

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.

Kesatuan Eropah - Iceland - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - doxórúbicín hýdróklóríð - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - Æxlishemjandi lyf - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

krka, d.d., novo mesto - prasugrelum inn - filmuhúðuð tafla - 10 mg

Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

krka, d.d., novo mesto - prasugrelum inn - filmuhúðuð tafla - 5 mg

Kesatuan Eropah - Iceland - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ruxolitinib phosphate - vitiligo - aðrar húðsjúkdómar - opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

Kesatuan Eropah - Iceland - EMA (European Medicines Agency)

sandoz pharmaceuticals d.d. - tópótecan - ovarian neoplasms; uterine cervical neoplasms; small cell lung carcinoma - Æxlishemjandi lyf - hycamtin hylki eru ætlaðar sem einlyfjameðferð til meðferðar hjá fullorðnum sjúklingum með endurkomið lungnakrabbamein í litlum frumum (sclc), sem ekki er talin endurmeðferð með fyrsta línunni.. tópótecan er ætlað fyrir sjúklinga með sjúklingum krabbamein eggjastokkum eftir bilun í fyrsta lína eða næstu meðferð. hycamtin hylki eru ætlaðar sem einlyfjameðferð til meðferðar hjá fullorðnum sjúklingum með endurkomið lungnakrabbamein í litlum frumum (sclc), sem ekki er talin endurmeðferð með fyrsta línunni..

Kesatuan Eropah - Iceland - EMA (European Medicines Agency)

pfizer europe ma eeig - tópótecan - uterine cervical neoplasms; small cell lung carcinoma - Önnur æxlishemjandi lyf - topotecan einlyfjameðferð er ætlað til meðferðar hjá sjúklingum með endurtekin lungnakrabbamein í litlum frumum (sclc) sem ekki er talin endurmeðferð með fyrstu línu meðferðinni.. tópótecan ásamt cisplatíni er ætlað fyrir sjúklinga með krabbamein í legháls endurtekin eftir geislameðferð og fyrir sjúklinga með stigi ivb sjúkdómur. sjúklingar með áður en útsetningu cisplatíni þurfa áframhaldandi meðferð-frjáls bili til að réttlæta meðferð við samsetningu.